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BACKGROUND: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. We tested megestrol acetate
(MA) against placebo in the treatment of advanced HCC.
METHODS: From 2002 through 2007, this randomised double-blind trial enrolled 204 patients with treatment-naive advanced HCC
(Eastern Cooperative Oncology Group (ECOG) performance rating of 0-3) from specialist care centres in six Asia-Pacific nations.
Patients received placebo or MA (320mgday
 1). End points were overall survival (OS) and quality of life.
RESULTS: An adverse but not statistically significant difference in OS was found for MA vs placebo: median values 1.88 and 2.14 months,
respectively (hazard ratio (HR)¼1.25, 95% CI¼0.92–1.71, P¼0.16). However, OS was similar among patients of good functional
status (Child-Pugh A and ECOG 0, 1 or 2) (44.3%) in both treatment groups, with the adverse effect of MA confined to those of
poor status. Megestrol acetate patients had a worse global health status (not statistically significant) but reduced levels of appetite loss
and nausea/vomiting.
CONCLUSION: Megestrol acetate has no role in prolonging OS in advanced treatment-naive HCC. Overall survival with placebo
differed markedly from that in similar trials conducted elsewhere, suggesting therapeutic outcomes may be strongly dependent on
ECOG status and Child-Pugh score.
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Hepatocellular carcinoma (HCC) is the fifth most common
malignancy and the third leading cause of cancer deaths worldwide
(El-Serag and Rudolph, 2007). However, its geographic distribu-
tion is varied and reflects the aetiology of the disease. Worldwide
54.4% of HCC are attributable to chronic hepatitis B and 31.1% to
chronic hepatitis C (Parkin et al, 2005). The disease is endemic to
the Asia-Pacific region, where B80% of HCC are found.
Surgical resection and (in carefully selected cases) liver
transplantation remain the therapeutic modalities that most
consistently prolong survival, but only 20% of patients are
amenable (Hung, 2005) at diagnosis. Another 30% may benefit
from loco-regional therapies (Llovet et al, 2003a). Before the
initiation of this trial (AHCC02) (ClinicalTrials.gov number
NCT00041275), phase III placebo-controlled randomised trials
for inoperable HCC had failed to demonstrate survival benefit
(Llovet and Bruix, 2003b; Nowak et al, 2004).
Specifically, oestrogen is known to influence the growth of HCC,
randomised controlled trials have not demonstrated positive
benefits with the anti-oestrogen tamoxifen (Chow et al, 2002;
Nowak et al, 2005), and this is attributed to the high incidence of
oestrogen receptor mutations (Villa et al, 1996, 2000; Liu et al,
2000; Chow et al, 2001). Megestrol acetate (MA), a synthetic
progestin with multiple drug actions and potent anti-oestrogen
activity at the post-receptor level, is independent of oestrogen
receptors. Consequently, MA has been widely used in the
management of advanced breast carcinoma that is resistant to
tamoxifen (Sedlacek, 1988).
Preclinical data have shown that human HCC xenografts
respond to MA in vivo (Zhang and Chow, 2004). Initial clinical
studies using MA at 160mgday
 1 in 46 and 11 patients,
respectively, did not demonstrate objective tumour response
(Colleoni et al, 1995; Chao et al, 1997). However, a phase III trial
using MA at 320mgday
 1 in 102 patients with advanced HCC
showed a significant doubling of median survival compared with
placebo (Phornphutkul et al, 1996), and a study of 45 patients with
inoperable HCC demonstrated a doubling of median survival using
MA at 160mgday
 1 (Villa et al, 2001). The latter suggested more
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spronounced results in patients with mutated oestrogen receptors.
In the Asia-Pacific region, the majority of HCC patients have such
mutations (Chow et al, 2001). Further, MA is frequently used in
patients with advanced malignancies to improve QOL (Bruera
et al, 1998) especially with respect to appetite (De Conno et al,
1998; Westman et al, 1999; Lesniak et al, 2008).
This paper reports on a multinational randomised double-blind
placebo-controlled trial of the Asia-Pacific Hepatocellular Carci-
noma (AHCC) Trials Group to assess the efficacy of MA in patients
with advanced HCC in terms of overall survival (OS) and QOL.
Given the positive results of the previous phase III trial using MA at
320mg and the negative results with the two smaller phase II trials
using MA at 160mg, this trial compares MA at 320mg vs placebo.
During the course of this trial, preliminary results were released
from another placebo-controlled randomised trial (Sorafenib
Hepatocellular Carcinoma Assessment Randomised Protocol
(SHARP); Llovet et al, 2008) (ClinicalTrials.gov number
NCT00105443) in advanced HCC patients who had good functional
reserves. The results of that trial, and a similar trial of sorafenib vs
placebo in the Asia-Pacific (SAP) (Cheng et al, 2009), (Clinical
Trials.gov number NCT00492752) were subsequently published.
The impact of this preliminary information on our AHCC02 trial is
reported.
PATIENTS AND METHODS
Patients
AHCC02 enrolled treatment-naive patients with advanced HCC
from clinicians in seven specialist clinical centres in six
Asia-Pacific nations: Myanmar, New Zealand, the Philippines,
Singapore, South Korea and Vietnam. Eligible patients were
representative of advanced HCC patients in the region for whom
there was no proven standard of care at that time. Diagnosis of
HCC was defined by positive histology, demonstration of a space-
occupying lesion of the liver by non-dynamic imaging (ultrasound,
CT scan or MRI) in patients with either a serum a-feto protein
level X400mgl
 1 or dense homogenous lipiodol retention, or
radiological evidence of HCC by dynamic contrast-enhanced CT
Scan MRI in patients with a-feto protein above the normal range
and serology positive for viral Hepatitis B or C. Patients were
excluded if they had clinical encephalopathy, had received prior
treatment for HCC (surgery including liver transplantation,
chemo-embolisation, percutaneous ethanol injection and systemic
chemotherapy) or were amenable to surgery. Other exclusion
criteria were pregnancy, another malignancy within the last 5
years, and serum bilirubin 4100mmoll
 1. The protocol con-
formed to the ethical guidelines of the 1975 Declaration of Helsinki
and was approved by the Institutional Review Boards of the
participating institutions. Written informed consent was obtained
before enrolment.
Trial design
In addition to receiving best supportive care, patients were
randomised to either placebo or MA 320mgday
 1 for 1 year.
Both placebo and MA were obtained from Bristol-Myers-Squibb.
The trial pharmacist at the Department of Pharmacy, Singapore
General Hospital was responsible for supplying placebo and MA,
packaged in a double-blind format, which were dispensed in
bottles identified by patient trial number by a named clinician at
each participating centre according to a randomisation code. At
monthly reviews, the responsible blinded clinician checked for
compliance in terms of dosage and frequency of drugs taken. After
treatment was completed, patients were followed up every 3 months.
Randomisation, conducted through the Singapore Clinical
Research Institute using a web-based system, was stratified by
recruiting centre using blocks of nine in order to retain the study
design’s allocation ratio of 2:1 in favour of MA.
End points
The primary end point was OS, defined as the time from
randomisation to the time of death or, if appropriate, when the
patient was last known to be alive. The secondary end point was
QOL, assessed using the European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life Questionnaire
(Aaronson et al, 1993), which was completed at screening and at
each follow-up visit by patients named assisting personnel. The
questionnaire is composed of five functional and nine symptom
scales/single items, and a Global Health Status (GHS) scale. Scores
(0–100) were calculated as recommended (Fayers et al, 2001).
A better QOL is indicated by high scores on the GHS
and functional scales, and low scores on the symptom
scales. Any serious adverse events (SAEs) experienced by patients
were elicited at each clinic visit.
Statistical methods
Trial size Previous experience in patients with advanced HCC
and Eastern Cooperative Oncology Group (ECOG) performance
rating of 0-2 in the Asia-Pacific suggested that OS at 6 months
would be 25% (Chow et al, 2002). We anticipated that this might
be improved to 45% with MA. On this basis, using an allocation
ratio of 2:1 in favour of MA, a two-sided test of 5% and 90%
power suggested that 220 patients would be required (Machin et al,
1997). However, the potential inclusion of patients with ECOG 3,
comprising B12% with the poorest prognosis and thought less
likely to benefit as much from MA (Chow et al, 2002), reduced the
anticipated 6-month rate to 42.6%. The corresponding hazard ratio
(HR)¼0.62 revised the target to 280, which was increased to 300
patients to compensate for potential losses.
Overall survival Overall survival was summarised using the
Kaplan–Meier technique and comparisons were made using Cox
regression to estimate the HR, 95% CI and P-value. Although
subgroup analyses were not part of the original design, we
conducted analyses comparing the specific patients from AHCC02
who had the same characteristics (in terms of ECOG and
Child-Pugh) as patients in the SHARP and SAP trials. This led to
a more detailed examination of the AHCC02 data with respect to
Child-Pugh class and ECOG status.
Quality of life Graphical plots were used to explore the pattern of
QOL changes over time. However, since QOL data take relatively
few values, such graphs have common plotting points for many
patients and thereby obscure individual patient contributions at
these points. To compensate, we introduced a small amount of
jittering of the plotting positions (surrounding each true position)
to reveal any multiplicity of observations. As QOL was assessed in
each patient over several time points, the corresponding compar-
ison between treatment groups was made using a linear model of
the form:
QOL ¼ b0 þ bTime t þ bTreat Treatment þ bInteraction tTreatment
where Treatment¼0 if placebo is given and 1 if MA is given, and
t represents the time post-randomisation the assessments were
made on the particular patient concerned. The regression
coefficients bTreat and bTime are obtained using the data from all
patients and represent the difference in QOL between treatments
and the linear change in QOL over time, respectively. Thus, the
null hypothesis of no difference between treatments is expressed
by bTreat¼0 and that of no change in QOL over time by bTime¼0.
Inclusion of the interaction term, hypothesis bInteraction¼0,
enables a test of whether differences between treatments remain
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sconstant over time. The coefficient b0 represents the average value
of all QOL assessments made.
The procedure xtmixed in Stata (StataCorp., 2007) was used to fit
this statistical model to each of the 15 EORTC end points. This
model takes into account the knowledge of which item of data is
from which patient and the variable number of observations per
patient. The correlation structure of observations from the same
patient has to be taken into account as does the possibility that each
patient will have their own trajectory of change with time. Since only
20% of patients survived beyond 6 months from randomisation, the
model fit is confined to this 6-month period. Once fitted, the model
was used to estimate the differences between treatment groups at 3
and 6 months post-randomisation. Although the same statistical
model is not the most appropriate for each QOL end point, the
above reflects the major features of the data.
RESULTS
Recruitment and trial monitoring
From March 2002 through June 2007, AHCC02 recruited 204 patients
with advanced HCC (68% of target) before the preliminary results of
204 Patients randomised
69 Placebo 135 Megestrol acetate
19 No data received
from one centre
62 Analysed by
intention-to-treat
123 Analysed by
intention-to-treat
Ineligible
1 prior treatment
Ineligible
2 prior treatment
4 serum bilirubin
>100 mol l–1
Non-compliance
8 discontinued
medication
Non-compliance
15 discontinued
medication
4 Lost to follow-up 11 Lost to follow-up
At trial end
3 completed 1-year
medication
59 deaths
At trial end
1 completed 1-year
medication
121 deaths
Figure 1 Consort diagram.
Table 1 Demographic and baseline characteristics of 185 patients
included in the intention-to-treat analysis
Characteristic Placebo Megestrol acetate
Number of patients (n) 62 123
Age (years)
Median 60.9 56.0
Range 31.1–80.9 20.1–100.3
Gender (%)
Male 51 (82.3) 108 (87.8)
Country (%)
Myanmar 17 (27.4) 33 (26.8)
New Zealand 3 (4.8) 6 (4.9)
Philippines 7 (11.3) 12 (9.8)
Singapore 18 (29.0) 36 (29.3)
South Korea 5 (8.11) 11 (8.9)
Vietnam 12 (19.4) 25 (20.3)
Ethnicity (%)
Chinese 15 (24.2) 34 (27.6)
Filipino 7 (11.3) 12 (9.8)
Indian 1 (1.6) 1 (0.8)
Korean 5 (8.1) 11 (8.9)
Malay 2 (3.2) 2 (1.6)
Myanmar 17 (27.4) 33 (26.9)
Vietnamese 12 (19.4) 25 (20.3)
Others 3 (4.8) 5 (4.1)
Hepatitis infection (%)
B 33 (53.2) 75 (61.0)
C 8 (12.9) 8 (6.5)
B and C 1 (1.6) 2 (1.6)
Unknown 20 (32.3) 38 (30.9)
History of significant alcohol consumption (%) 8 (12.9) 26 (21.1)
ECOG status (%)
0: Normal activity 14 (22.6) 12 (9.8)
1: Symptoms 33 (53.2) 69 (56.1)
2: In bed p 50% day 13 (21.0) 30 (24.4)
3: In bed 4 50% day 2 (3.2) 12 (9.8)
Child-Pugh class (%)
A 27 (43.5) 59 (48.0)
B 25 (40.3) 45 (36.6)
C 8 (12.9) 16 (13.0)
Unknown 2 (3.2) 3 (2.4)
Functional status (Child-Pugh & ECOG) (%)
Good 26 (41.9) 56 (45.5)
Poor 34 (54.8) 64 (52.0)
Unknown 2 (3.2) 3 (2.4)
TNM (%)
II 12 (19.4) 10 (8.1)
IIIA 16 (25.8) 33 (26.8)
IIIB 2 (3.2) 6 (4.9)
IVA 16 (25.8) 41 (33.3)
IVB 10 (16.1) 17 (13.8)
Unknown 6 (9.7) 16 (13.0)
Okuda stage (%)
I 17 (27.4) 20 (16.3)
II 35 (56.5) 79 (64.2)
III 10 (16.1) 21 (17.1)
Unknown 1 (1.6) 6 (4.9)
EORTC global health status
n 57 111
Median 50 50
Range 16.7–100 0–100
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; TNM¼tumour,
nodes and metastases; EORTC¼European Organisation for Research and
Treatment of Cancer.
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sthe SHARP trial (Cheng et al, 2009) became available (4 June 2007).
SHARP had enrolled 602 HCC patients but with good liver function of
Child-Pugh A and ECOG 0-2 to compare oral sorafenib against
placebo in terms of OS and time to symptomatic progression. They
found a median OS almost 3 months longer with sorafenib than with
placebo (HR¼0.69, 95% CI¼0.55–0.87, Po0.001). Consequently,
the ongoing AHCC02 was reviewed by the Trial Steering Committee,
which concluded that the use of a placebo was no longer ethical. At
t h ea d v i c eo ft h eS t e e r i n gC o m m i ttee, the AHCC02 was prematurely
closed on 14 June 2007, a decision taken without a formal review of
the still blinded AHCC02 trial data. One year after the SHARP results,
similar benefits for sorafenib were announced from a parallel trial
(SAP) (Cheng et al,2 0 0 9 )i na na l l - A s i a np o p u l a t i o no f2 2 6p a t i e n t s
(HR¼0.68, 95% CI¼0.50–0.93, Po0.014).
Patient characteristics
Figure 1 summarises the flow of the 204 randomised AHCC02
patients through the trial (135 randomised to MA and 69
randomised to placebo). The majority of patients were male
(85.9%) and most were recruited from centres in Singapore
(29.2%), Myanmar (27.0%) and Vietnam (20.0%) (Table 1).
Chronic hepatitis B infection was identified in 58.4%, C in 8.6%
and co-infection in 1.6%. The majority (102 out of 185, 55.1%)
presented with ECOG 1 status and 14 out of 185 (7.6%) were ECOG
3. There were 37.8% of Child-Pugh A, 37.8% B and 13.0% C. Their
median EORTC GHS was 50 (range 0–100). No data were received
from one centre (and the centre was subsequently withdrawn)
from the trial. Final analysis was thus based on 185 patients.
Overall survival
A total of 180 out of 185 (97.3%) patients had died by the time of
final data analysis, including 59 out of 62 (95.2%) who received
placebo and 121 out of 123 (98.4%) who received MA. The
Kaplan–Meier OS estimates (Figure 2A) at 6 months were 21.76%
for placebo and 15.01% for MA. Corresponding median values
were 2.14 and 1.88 months, respectively, with an adverse HR¼1.25
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Figure 2 AHCC02 Kaplan–Meier estimates of OS. (A) OS by treatment. (B) OS in good and poor risk groups as defined by Child-Pugh class and ECOG
performance status.
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s(95% CI¼0.92–1.71, P¼0.16) for MA. After adjusting individu-
ally for Child-Pugh class and ECOG status, the corresponding
HRs for placebo and MA were 1.37 (CI¼0.98–1.91, P¼0.06) and
1.01 (CI¼0.73–1.40, P¼0.95), respectively. The former suggests a
possible adverse effect of MA on OS, while the latter suggests no
benefit of MA over placebo. The median period of administration
of MA was 1.57 (range 0.03–13.67) months and that of placebo was
1.35 (range 0.03–15.16) months.
Adverse events and quality of life
The SAEs were fairly evenly distributed between the two groups.
Fifty SAEs (15 in placebo (P) and 35 in MA) were reported in 38
(13 in P and 25 in M) patients. The SAEs are shown in Table 2.
Considerable variation in GHS was seen between patients and over
time, with a suggestion of increasing values with placebo but
decreasing values with MA (Figure 3). An appropriate model, fitted
using the assumption of an unstructured (or no pattern)
correlation between successive within-patient measurements and
a random effect for the assumed linear change over time for each
patient, was:
GHS ¼ 52:681 þ 0:2145 t   2:8219 Treatment
  2:04 t Treatment
For this model, the P-values for change in GHS over time,
Treatment and Interaction (t Treatment) were 0.877, 0.360 and
0.253, respectively, none of which was statistically significant. This
confirms a general but small increase in GHS over the 6-month
post-randomisation, with those receiving MA taking lower values.
This adverse difference for MA was 8.97 at 3 months and 15.12 at 6
months post-randomisation (Table 3). The difference of 2.82
reported between treatments at baseline represents a random
difference.
Patients who received placebo generally had a more favourable
QOL profile, though for most scales the estimated differences were
negligible. Emotional functioning marginally favoured MA but the
advantage at 6 months was smaller in magnitude than the random
difference at baseline. Megestrol acetate also had favourable
reductions in levels of appetite loss and nausea/vomiting
compared with placebo.
DISCUSSION
When this multicentre multinational double-blind trial of patients
with advanced treatment-naive HCC commenced in 2002, it was
designed to reflect the actual patient population with inoperable
HCC in the Asia-Pacific rather than the better subset of patients
with Child-Pugh A liver function. At the time the trial started, there
were no phase III data to suggest that any treatment was superior
to placebo or best supportive care in patients with inoperable HCC.
This prematurely terminated trial failed to show the anticipated
increase in OS with MA over placebo, and patients on placebo
generally had better outcomes in terms of QOL. Interestingly, in
spite of its premature termination and due to the greater-than-
expected death rate with MA, the analysis presented here includes
information on the exact number of deaths (n¼180) that had been
expected with full recruitment, hence preserving the robustness of
the planned data analysis.
Patients recruited to the SHARP and SAP trials were all ECOG 0-2
and the vast majority were Child-Pugh A (581 out of 602 (96.5%) and
220 out of 226 (97.3%), respectively). In contrast in the AHCC02, 82
out of 185 (44.3%) patients were Child-Pugh A and ECOG 0, 1 or 2
(Table 1). These patients were classified as having good functional
status and the remainder, including five cases in which category was
unknown, were defined as having poor functional status. The
corresponding Kaplan–Meier estimates of OS (Figure 2B) indicate
an adverse effect of MA in those of poor functional status (HR¼1.79,
CI¼1.15–2.80, P¼0.01), but suggest a possible benefit in those of
good functional status (HR¼0.82, CI¼0.51–1.33, P¼0.42). Inter-
estingly, 6-month OS differed markedly between AHCC02 patients of
good status who were on placebo (22%) and similar SAP trial
patients who were on placebo (37%).
The estimated HRs for comparing treatments of patients with
Child-Pugh score A vs B–C (Figure 4) suggest a possible advantage
with MA in those of Child-Pugh A. In contrast, comparing ECOG
groups 0-1 and 2-3 suggests near equivalence of the two regimens.
In our subgroup analyses, we found little difference in OS
between treatments among those who had good functional status,
but evidence of an adverse outcome with MA in those who did not.
Although we acknowledge the limitations and non-confirmatory
nature of findings from such a subset analysis, our results are
suggestive of potential differentials among the prognostic groups.
Our results also suggest that outcomes of systemic therapy for
HCC patients with good functional status may not necessarily
apply to patients with poor functional status. Hepatocellular
carcinoma is a complex cancer where OS is significantly influenced
by underlying liver disease that impacts drug metabolism and
toxicities. Thus, while it is tempting to extrapolate the results of
Table 2 Serious adverse events
SAE description (%)
Placebo
(n¼15)
MA
(n¼35)
All SAE
(n¼50)
Ascites 4 (26.7) 4 (11.4) 8 (16.0)
GI bleed 0 (0) 7 (20.0) 7 (14.0)
Jaundice 1 (6.7) 6 (17.1) 7 (14.0)
Death 2 (13.3) 4 (11.4) 6 (12.0)
Abdominal pain 1 (6.7) 4 (11.4) 5 (10.0)
Anemia 1 (6.7) 3 (8.6) 4 (8.0)
Tumour rupture 2 (13.3) 1 (2.9) 3 (6.0)
Pneumonia 1 (6.7) 1 (2.9) 2 (4.0)
Admitted for UTI 1 (6.7) 0 (0) 1 (2.0)
Admitted for limb pain 0 (0) 1 (2.9) 1 (2.0)
Chest pain 0 (0) 1 (2.9) 1 (2.0)
Cholangitis 1 (6.7) 0 (0) 1 (2.0)
Epistaxis 0 (0) 1 (2.9) 1 (2.0)
Fall 0 (0) 1 (2.9) 1 (2.0)
Hypoglycaemia 0 (0) 1 (2.9) 1 (2.0)
Unknown 1 (6.7) 0 (0) 1 (2.0)
Abbreviations: GI¼gastro-intestinal; MA¼megestrol acetate; SAE¼serious adverse
event; UTI¼urinary tract infection. Fifty SAEs (15 in placebo and 35 in MA) were
reported in 38 (13 in placebo and 25 in MA) patients. The most happened SAEs
were Ascites (8), GI Bleed (7) and Jaundice (7). The most happened SAEs in MA
group were GI Bleed (7) and Jaundice (6).
0
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Figure 3 Changes in EORTC GHS over time by treatment group with
the fitted model for the first 12 months post-randomisation.
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spositive trials in patients with good functional status to patients
with poor functional status, such extrapolation must be treated
with caution in the absence of suitably powered double-blind trials
(Kelley and Venook, 2008).
The markedly lower OS for AHCC02 patients of good status who
were on placebo compared with SAP patients on placebo is
remarkable given that patients in both trials were largely similar in
ethnicity and aetiology for HCC. A possible reason for this
discrepancy lies in differences in eligibility criteria. AHCC02
enrolled only patients who were treatment naive and thus had
advanced disease at the time of diagnosis, while SAP also enrolled
patients who had previously received other loco-regional therapies
such as surgery, radiotherapy, hepatic artery embolisation, chemo-
embolisation, radiofrequency ablation, percutaneous therapy or
cryoablation. The natural history of such patients differs from
those who have advanced disease at diagnosis. For example, Asian
patients with recurrent HCC following the initial surgery have
1-, 3- and 5-year survival rates of 77%, 49% and 26%, respectively,
after tumour recurrence (Poon et al, 2002). Similarly, the largest
reported case series in Asia showed that selected Child-Pugh A
patients with advanced HCC who received hepatic artery
embolisation had 1-, 3- and 5-year survival rates of 29.5%, 6.0%
and 4.4%, respectively (Wang et al, 2008). The natural history of
these patients is significantly better than that of the treatment-
naive patients with advanced disease on the placebo arm of our
trial, which showed a 1-year survival rate of 9.1% for those with
Child-Pugh’s A and ECOG 0-1. Similarly, we found a 1-year
survival rate for such patients of 11.3% in our previous AHCC01
trial, which recruited a sample consistent with the present trial
regarding ethnic composition, treatment-naivete and proportion of
patients of poor functional status (Child-Pugh B, C or ECOG 3).
The SAP trial did not report the proportion that had received loco-
regional therapies, but the inclusion of such patients in
randomised trials of systemic therapy would be expected to result
in a better OS when compared with trials that only recruit patients
with advance disease at presentation.
Regarding QOL, patients on placebo experienced little change
overall in their EORTC GHS from baseline to 6 months, while those
on MA exhibited a decline. Of the six functional scales, all except
emotional functioning (which demonstrated little difference
between treatments) suggested less favourable values with MA
compared with placebo. Among the nine symptom scales, appetite
loss and nausea/vomiting improved with MA compared with
placebo, while all other scales marginally declined with MA.
In conclusion, the AHCC02 trial suggests that those receiving
treatment for HCC who had poor functional status showed a
poorer outcome with MA than with P, while those of good
functional status showed similar outcome with both treatments.
Overall, though we found some benefit with MA with respect to
improving appetite and reducing nausea/vomiting, the GHS and
other aspects of QOL showed no improvement with MA.
Consequently, we recommend that MA not be used for the
treatment of HCC.
Table 3 Model estimates of EORTC QOL mean symptom and scale
values at baseline, 6 and 12 months post-randomisation and the
corresponding estimated differences between treatments
a
EORTC scales Baseline 3 months 6 months Favours MA
Global health status (GHS)
Placebo 52.68 53.33 53.97
MA 49.85 44.36 38.85
Difference  2.82  8.97  15.12 No
Physical functioning
Placebo 74.01 44.06 14.11
MA 67.02 38.84 10.65
Difference  6.99  5.23  3.46 No
Role functioning
Placebo 64.10 56.68 49.26
MA 60.79 45.83 30.86
Difference  3.31  10.86  18.40 No
Emotional functioning
Placebo 74.17 72.68 71.19
MA 71.35 71.98 72.62
Difference  2.82  0.69 +1.43 Yes
Cognitive functioning
Placebo 80.56 78.20 75.85
MA 74.74 69.71 64.68
Difference  5.82  8.49  11.17 No
Social functioning
Placebo 69.77 69.35 68.94
MA 71.88 66.56 61.23
Difference +2.11  2.80  7.70 No
Fatigue
Placebo 39.63 53.86 68.08
MA 47.11 59.29 71.46
Difference +7.48 +5.43 +3.38 No
Nausea/vomiting
Placebo 11.95 23.59 35.23
MA 11.47 6.99 2.51
Difference  0.48  16.60  32.73 Yes
Pain
Placebo 34.50 38.50 42.49
MA 37.39 41.58 45.87
Difference +2.79 +3.08 +3.37 No
Dyspnoea
Placebo 22.25 38.19 54.13
MA 28.24 45.75 63.27
Difference +5.99 +7.56 +9.13 No
Insomnia
Placebo 29.75 33.84 37.93
MA 33.06 41.13 49.20
Difference +3.32 +7.29 +11.27 No
Appetite loss
Placebo 40.28 37.74 35.20
MA 38.14 24.82 11.50
Difference  2.13  12.92  23.70 Yes
Constipation
Placebo 20.55 18.17 15.79
MA 16.46 17.87 18.48
Difference  4.09 +0.31 +2.69 No
Diarrhoea
Placebo 13.36 11.43 9.50
MA 15.34 13.47 10.95
Difference +1.98 +2.04 +1.45 No
Table 3 (Continued)
EORTC scales Baseline 3 months 6 months Favours MA
Financial problems
Placebo 40.34 37.49 34.64
MA 40.46 44.75 48.09
Difference +1.98 +2.04 +1.45 No
Abbreviations: EORTC¼European Organisation for Research and Treatment of
Cancer; MA¼megestrol acetate; QOL¼quality of life.
a168 out of 185 (90.8%) of
patients completed the baseline (0 month) QOL assessment and returned 482 out of
701 (68.8%) of anticipated QOL assessments.
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